Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | QPCT | Q16769 | 12/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649372 | 0.87 | ADRA2A (0.51) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL19558168 | 0.86 | ADRA2A (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL11557199 | 0.82 | NAMPT (0.52) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2544250 | 0.82 | QPCT (0.67) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2545182 | 0.82 | EPHX1 (0.48) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL5063947 | 0.80 | ADRA2A (0.58) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2541647 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL16434608 | 0.77 | QPCT (0.47) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL28086633 | 0.77 | EPHX1 (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL11580425 | 0.77 | QPCT (0.63) | QPCTNAMPTHTTMAPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ADRA2A 3346/4885ADRA2C 3128/4885ADRA1D 725/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ADRA2A 3346/4885ADRA2C 3128/4885ADRA1D 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.